Business Context and Reporting Period
Company: Shoulder Innovations, Inc. (SI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A commercial-stage medical technology company focused on shoulder arthroplasty implant systems (anatomic and reverse). The company utilizes a third-party manufacturing model and sells through a network of distributors and independent sales representatives in the United States. The company completed its IPO in August 2025 and is classified as an Emerging Growth Company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Net Revenue | $17,175 | $33,883 | $21,145 |
| Gross Profit | $13,441 | $26,427 | $16,184 |
| Gross Margin | 78.3% | 78.0% | 76.5% |
| Operating Loss | $(10,036) | $(19,012) | $(10,156) |
| Net Loss | $(10,153) | $(18,532) | $(23,858) |
| Adjusted EBITDA | $(8,023) | $(14,980) | $(21,573) |
| Cash & Cash Equivalents | $24,460 (as of June 30, 2026) | ||
| Marketable Securities | $74,533 (as of June 30, 2026) | ||
| Total Liquidity | $98,993 (as of June 30, 2026) | ||
| Long-Term Debt | $14,813 (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 56.0% year-over-year for the quarter and 60.2% for the six-month period, driven by a 49.8% increase in implant systems sold (2,238 units in Q2 2026 vs. 1,503 in Q2 2025) and an expanded customer base.
- Expense Expansion: Operating expenses increased significantly. Selling, General, and Administrative (SG&A) expenses rose 56.3% (quarter) and 64.0% (six months) due to headcount growth, higher commissions, and increased public company costs. Research and Development (R&D) expenses surged 141.2% (quarter) and 139.0% (six months), primarily due to a strategic partnership for a robotic platform.
- Profitability: While the Net Loss narrowed by 47.1% for the quarter and 22.3% for the six months compared to the prior year, the company remains unprofitable. The improvement in Net Loss was aided by the absence of a $11.7 million fair value adjustment on Series E purchase options recorded in the prior year.
- Debt Restructuring: In June 2026, the company refinanced its debt, entering a new Loan Agreement with Stifel Bank for a $15 million term loan and a $30 million revolving facility, replacing the previous Trinity Loan Agreement. This resulted in a $589 thousand loss on extinguishment of debt.
Guidance, Outlook, and Risks
- Product Pipeline: The company is developing "InSet Neo," a shoulder-specific micro-robotic solution, with FDA submission planned for the first half of 2027. New products including the InSet I-135RFX Humeral Stem and InSet Clutch guide system have been launched or are in release phases.
- Liquidity Outlook: Management believes existing cash, marketable securities ($98.9 million total), and the new credit facility are sufficient to fund operations for at least 12 months. The company expects to continue incurring losses as it scales its commercial organization and R&D.
- Key Risks:
- Litigation: Ongoing patent infringement lawsuit against Catalyst Orthoscience Inc., with a counterclaim filed by Catalyst. No accrual has been made as the outcome is uncertain.
- Reimbursement: Dependence on third-party payors (Medicare, Medicaid, private insurers) and potential downward pricing pressure in the medical device industry.
- Seasonality: Historically lower demand in the third calendar quarter due to summer seasonality.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Stifel Bank Loan Agreement covenants, particularly regarding liquidity requirements and borrowing base calculations for the revolving facility.
- Related Party Transactions: Review the ongoing software license and consulting agreements with Genesis Software Innovations, LLC (affiliated with the CEO), noting the $4.3 million paid in the first six months of 2026.
- Robotics Partnership: Assess the financial impact and milestones of the strategic partnership driving the 141% increase in R&D expenses.
- Legal Exposure: Monitor the status of the Catalyst Orthoscience litigation and potential counterclaim liabilities.
- Inventory Levels: Review the increase in inventory ($22.9 million) relative to sales growth to ensure no obsolescence risks are emerging.